Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

Bristol Myers Squibb Company is under pressure to bring new drugs to market before several of its current blockbuster products face generic and biosimilar competition. But in addition to a suite of late-stage and newly approved therapies that it believes will generate more than $25bn in new revenue by 2029, the company has a rapidly growing pipeline of Phase I and II research and development programs with many drug candidates on the cusp of proof-of-concept data or nearing advancement into Phase III.

Bristol showcased some of its early and mid-stage clinical programs that may help BMS grow its revenue base later in...